A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells

Mingxing Hu; Chao Yang; Yi Luo; Fan Chen; Fangfang Yang; Shuping Yang; Hao Chen; Zhiqiang Cheng; Kun Li; Yongmei Xie

doi:10.1039/C8TB00546J

A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells†

Mingxing Hu,‡^a Chao Yang,‡^a Yi Luo,^a Fan Chen,^a Fangfang Yang,^a Shuping Yang,^a Hao Chen,^a Zhiqiang Cheng,

^b Kun Li

^ac and Yongmei Xie

*^a

Author affiliations

* Corresponding authors

^a State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, P. R. China
E-mail: xieym@scu.edu.cn

^b Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^c Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry Sichuan University, 29, Wangjiang Road, Chengdu, P. R. China

Abstract

Herein, a novel soluble mitochondria-targeted theranostic compound, HMX-1, was presented, which was selectively activated under hypoxia with excellent mitochondria-targeting ability at the cellular level, accompanied by a dramatic increase in the fluorescence intensity. Moreover, its anti-cancer efficiency was certified both in vitro and in vivo.

Journal of Materials Chemistry B

A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells†

Abstract

Associated articles

Supplementary files

Article information

Download Citation

Permissions

A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells

Social activity

Search articles by author

Spotlight

Advertisements